Proteus Digital Health

Back to Press Releases
17 January, 2019

Proteus Digital Health® Launches Digital Oncology Medicines to Improve Patient Outcomes  

Proteus, Fairview Health Services, and University of Minnesota Health are First to Provide Digital Medicines to Cancer Patients

January 17, 2019 – REDWOOD CITY, Calif. and MINNEAPOLIS, Minn. – Proteus Digital Health®, Inc., Fairview Health Services, and University of Minnesota Health announced today that for the first time cancer patients are using digital oncology medicines to support treatment regimens and improve outcomes. This advancement helps patients complete oral chemotherapy cycles while oncologists gain new insights into their patients’ treatment progress and overall health status. Proteus, Fairview, and University of Minnesota Health unveiled the care model for digital oncology medicines and a collaboration with the University of Minnesota, at the ASCO-GI 2019 Gastrointestinal Cancers Symposium in San Francisco.

Proteus developed the care model for oral digital oncology medicines with University of Minnesota Health and Fairview, which is the first health system in the world to prescribe digital capecitabine, a common chemotherapy drug prescribed with the Proteus ingestible sensor. Currently it is being used to help treat stage 3 and 4 colorectal cancer patients.

“Proteus has given us a great opportunity to take our passion for better care management of patients receiving oral oncolytics and move that forward, because we were starting to reach the limits of our current way of doing things,” said University of Minnesota Physicians oncologist/hematologist Dr. Edward Greeno, who also directs the University of Minnesota Health oncology service line. “Proteus’ digital oral chemotherapy provides a much more direct connection to the patient. It creates a way for us to achieve a lot of things that happen when a patient is in the clinic for infusions without them coming in person. Also, we can learn things about the patient that we can’t learn from an office visit, like how the patient is doing with their treatment regimen while at home, on a daily basis.”

The digital medicines program helps optimize treatment regimens while maintaining a patient’s privacy. The program securely captures, records, and shares information about the time, dose, and type of oral chemotherapy medication taken. This information, as well as data on rest, activity, and resting heart rate, can be shared with the patient’s consent with their physician, pharmacist, or caretaker. The information can only be seen by the patient and their designated individuals on a secure, mobile-friendly platform developed by Proteus.

“Currently, providers make decisions about oral chemotherapy based on patients’ best knowledge of their medication taking,” said Andrew Thompson, CEO and Co-founder of Proteus Digital Health. “For the first time, digital oncology medicines give providers and caregivers new insights and ability to engage with more specific information in the remote care of colorectal cancer patients. Based on our data around the use of digital medicines in other treatment areas, we believe this will enable oncology patients to stay on their therapy longer, avoid hospital admissions, and have better response to therapy overall.”

“Given the costs, complexity, and toxicity risk for oral chemotherapy, digital oncology medicine is an exciting step forward in cancer care,” says Paul Morales, PharmD, BCOP, Fairview Infusion Pharmacy manager at the University of Minnesota Health Clinics and Surgery Center. “For pharmacists, it helps us identify patients who might be struggling to take their medication correctly and intervene, for example by giving them a call to explain how to safely move forward if they do miss a dose. For patients, it helps them feel in control as they take a more active role in managing their medication. The results are better outcomes for patients.”

To gather more real-world experience and data from cancer patients using digital medicines, Proteus is launching a digital oral oncolytic medication registry. This study will gather data from multiple sites spanning academic medical centers to community practices and urban to rural facilities. Patients from participating sites will be prescribed digital capecitabine to assist them in their treatment. Data collected from the study will be used to share best practices across many sites, enabling richer data and outcome analysis.

“Proteus’ expansion of support for digital medicines into the oncology treatment area is not only important for patients and providers, it will be a game changer for the industry developing therapies intended to one day eradicate cancer,” said Olivia Ware, Proteus’ new Senior Vice President of US Markets and Franchise Development, who brings more than 15 years of commercial oncology experience from across a number of biopharma companies. Data gathered from digital oral oncolytics will enable cancer drugs and treatment regimens to be optimized to work their best for each individual patient, something not possible until now.”

About Proteus Digital Health®

Proteus Digital Health is enabling a new category of pharmaceuticals: Digital Medicines. These include widely used drugs, formulated so they communicate when they have been ingested; a wearable patch that detects medicines and captures physiologic response; mobile applications to support patient self-care and physician decision-making; and data analytics to serve the needs of health system managers. The company has more than 540 issued patents that protect this enabling technology, and regulatory clearances in the U.S., European Union and China.

Proteus Digital Health is privately held by investors that include Carlyle, Essex Woodlands, Kaiser Permanente®, Medtronic®, Novartis®, Otsuka, and ON Semiconductor®. Further information is available at: www.proteus.com.  Connect with us on Twitter @ProteusDH.

About  Fairview Health Services

Fairview Health Services (fairview.org) is a Minneapolis-based nonprofit health system driven to heal, discover and educate for longer, healthier lives. Founded in 1906, Fairview provides exceptional care to patients and communities as one of the most comprehensive and geographically accessible systems in Minnesota. Fairview has enjoyed a long partnership with the University of Minnesota and University of Minnesota Physicians, which is represented in the University of Minnesota Health brand. Together, we offer access to breakthrough medical research and specialty expertise as part of a continuum of care that reaches all ages and health needs. In 2018, we extended our partnership, with work underway to build an academic health system focused on patient-centered care, innovation, and clinical excellence.

 About University of Minnesota Health

University of Minnesota Health represents a collaboration between University of Minnesota Physicians and University of Minnesota Medical Center. Working together, we provide exceptional care in a wide range of specialties at our hospitals, clinics and in community-based facilities throughout the region. Visit: www.mhealth.org.

Press contacts:

Emily Fox, Director of Communications

Proteus Digital Health, Inc.

Tel: +1 650.637.6240

Email: efox@proteus.com

Krystle Barbour, Media Relations Manager

Office of Communications – Medical School
University of Minnesota | med.umn.edu
Office: 612-626-2767
Email: kbarbour@umn.edu

Press Office

For product images, video footage and interview requests, please contact the Proteus Press Office. Media requests only.

Contact Us

For general inquiries regarding Proteus or our products:

Proteus Digital Health, Inc.
2600 Bridge Parkway
Redwood City, CA 94065
P.
+1.650.632.4031
F.
+1.650.632.4071
3956 Point Eden Way
Hayward, CA 94545
P.
+1.650.637.6403